Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2 RANDOMIZED CLINICAL TRIAL OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN SUBJECTS WITH RECURRENT HIGH GRADE SEROUS OVARIAN CANCER.

Next Previous
Search
Trial Profile

A PHASE 2 RANDOMIZED CLINICAL TRIAL OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN SUBJECTS WITH RECURRENT HIGH GRADE SEROUS OVARIAN CANCER.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veliparib (Primary) ; Doxorubicin liposomal; Temozolomide
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie

    • Most Recent Events

    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Mar 2013 Planned end date changed from 1 Mar 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 17 Oct 2012 New source identified and integrated (M.D. Anderson Cancer Center, 2010-0230).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top